AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28445476 — intervention group
Group type: EXPERIMENTAL
Intervention: Online get-out-the-vote message
Number of subjects: 0
Study 28445476 — intervention group
Group type: EXPERIMENTAL
Intervention: Close friends of those who received the message
Number of subjects: 0
Study 25577201 — intervention group
Group type: EXPERIMENTAL
Intervention: GflaxLC (32% of carbohydrate and 60g of flaxseed powder per day)
Number of subjects: 27
Study 25577201 — intervention group
Group type: COMPARATOR
Intervention: GriceLC (35% of carbohydrate and 60g of raw rice powder per day)
Number of subjects: 27
Study 23720981 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation (50 mg per meal, three times a day)
Number of subjects: 144
Study 23720981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically appearing)
Number of subjects: 144
Study 21083540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (0.5 mg/kg bolus, 83.3 microg/kg/h infusion for 48 h)
Number of subjects: 52
Study 21083540 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1 microg/kg bolus, 0.17 microg/kg/h infusion for 48 h)
Number of subjects: 52
Study 19407226 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA
Number of subjects: 100
Study 19407226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17538877 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral prophylaxis
Number of subjects: 1256
Study 17538877 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning at 6 months
Number of subjects: 1256
Study 15534261 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; beta carotene, 15 mg)
Number of subjects: 2166
Study 15534261 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and copper (zinc, 80 mg; cupric oxide, 2 mg)
Number of subjects: 2166
Study 15534261 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants plus zinc and copper
Number of subjects: 2166
Study 15534261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2166
Study 16313112 — intervention group
Group type: EXPERIMENTAL
Intervention: Feiyangqin Rectum Condensed Liquid (FRCL)
Number of subjects: 72
Study 16313112 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (control)
Number of subjects: 72
Study 10588093 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 217
Study 10588093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 8905537 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Error group (n = 11)
Number of subjects: 23
Study 8905537 — intervention group
Group type: COMPARATOR
Intervention: No Initial Error group (n = 12)
Number of subjects: 23
Study 8905537 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on the WCST for all subjects
Number of subjects: 23
Study 8905537 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous error history
Number of subjects: 23
Study 1671326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 12
Study 1671326 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol
Number of subjects: 12
Study 1671326 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 12
Study 1671326 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 12
Study 6295339 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation cephalosporins (moxalactam disodium, cefotaxime sodium, cefoperazone sodium)
Number of subjects: 808
Study 6295339 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin sulfate plus clindamycin
Number of subjects: 808
Study 31606455 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 5 to 10 mg daily
Number of subjects: 17
Study 30367320 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning support
Number of subjects: 320
Study 30367320 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 320
Study 30367320 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 320
Study 28854396 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 20 min a week of minimally supervised (3MS)
Number of subjects: 573
Study 28854396 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 60 min a week of supervised high-intensity strength training (1WS)
Number of subjects: 573
Study 28854396 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 20 min a week of supervised high-intensity strength training (3WS)
Number of subjects: 573
Study 28854396 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 × 7 min a week of supervised high-intensity strength training (9WS)
Number of subjects: 573
Study 28854396 — intervention group
Group type: COMPARATOR
Intervention: Reference group without training (REF)
Number of subjects: 573
Study 26561301 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT
Number of subjects: 156
Study 26561301 — intervention group
Group type: EXPERIMENTAL
Intervention: OO
Number of subjects: 156
Study 26561301 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT and SO
Number of subjects: 156
Study 26561301 — intervention group
Group type: COMPARATOR
Intervention: SOD, MDA, GSH‐Px, and T‐AOC
Number of subjects: 156
Study 25001959 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (‐30% energy)
Number of subjects: 0
Study 21735193 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid-moistened misoprostol tablets
Number of subjects: 322
Study 21735193 — intervention group
Group type: COMPARATOR
Intervention: Dry misoprostol tablets
Number of subjects: 322
Study 19054024 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 280
Study 19054024 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 280
Study 18086984 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic telerounds
Number of subjects: 270
Study 18086984 — intervention group
Group type: COMPARATOR
Intervention: Standard bedside rounds
Number of subjects: 270
Study 15136504 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment (MTP-493GG genotype)
Number of subjects: 1740
Study 15136504 — intervention group
Group type: COMPARATOR
Intervention: MTP-493GT genotype
Number of subjects: 1740
Study 15136504 — intervention group
Group type: COMPARATOR
Intervention: MTP-493TT genotype
Number of subjects: 1740
Study 15136504 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 1740
Study 12365880 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 220
Study 12365880 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 220
Study 12365880 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 220
Study 12365880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 9572789 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation (100 Hz) during inspiration with inspiratory load
Number of subjects: 10
Study 7924329 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ corneal excision (IS)
Number of subjects: 24
Study 7924329 — intervention group
Group type: COMPARATOR
Intervention: Whole globe enucleation (EN)
Number of subjects: 24
Study 29570475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 29570475 — intervention group
Group type: COMPARATOR
Intervention: Control (high-dose corticosteroids)
Number of subjects: 0
Study 27883227 — intervention group
Group type: EXPERIMENTAL
Intervention: Music their mothers listened to during pregnancy
Number of subjects: 42
Study 27883227 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 42
Study 27883227 — intervention group
Group type: COMPARATOR
Intervention: Recorded lullabies
Number of subjects: 42
Study 26272328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast food consumption after high intensity interval exercise (HIIE)
Number of subjects: 10
Study 26272328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast food consumption after moderate intensity exercise (MIE)
Number of subjects: 10
Study 26272328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast food consumption after no exercise (NE)
Number of subjects: 10
Study 26272328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast food consumption in type 2 diabetes individuals
Number of subjects: 10
Study 26272328 — intervention group
Group type: COMPARATOR
Intervention: Fast food consumption in controls
Number of subjects: 10
Study 23299763 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute oral antioxidant cocktail (AOC, vitamins C and E, and alpha‐lipoic acid)
Number of subjects: 10
Study 23299763 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 23299763 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute oral antioxidant cocktail (AOC, vitamins C and E, and alpha‐lipoic acid) in patients with high basal free radicals
Number of subjects: 10
Study 23299763 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute oral antioxidant cocktail (AOC, vitamins C and E, and alpha‐lipoic acid) in patients with low basal free radicals
Number of subjects: 10
Study 21943625 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF stretching before eccentric exercise
Number of subjects: 28
Study 21943625 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PNF stretching)
Number of subjects: 28
Study 18241359 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (n=19)
Number of subjects: 38
Study 18241359 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated (n=19)
Number of subjects: 38
Study 16856899 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth debridement with water
Number of subjects: 36
Study 16856899 — intervention group
Group type: COMPARATOR
Intervention: Quadrant-wise debridement
Number of subjects: 36
Study 16856899 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth debridement with povidone iodine
Number of subjects: 36
Study 16856899 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth debridement (both types)
Number of subjects: 36
Study 12639160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba 120 mg
Number of subjects: 0
Study 12639160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11043871 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional-exercise treatment group (AT group)
Number of subjects: 59
Study 11043871 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment group (RT group)
Number of subjects: 59
Study 11043871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AT and RT)
Number of subjects: 59
Study 11043871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsymptomatic patients
Number of subjects: 59
Study 9124404 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor (IGF-I) 100 microg/kg subcutaneously every 12 h for 6 doses
Number of subjects: 54
Study 9124404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 9702254 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral and immunostimulative treatment with Romanian specific products
Number of subjects: 16
Study 3520161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia and warm blood cardioplegia (hot shot)
Number of subjects: 20
Study 3520161 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 20
Study 29705482 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR) for eight weeks
Number of subjects: 91
Study 29705482 — intervention group
Group type: COMPARATOR
Intervention: Routine cares (Control)
Number of subjects: 91
Study 27419471 — intervention group
Group type: EXPERIMENTAL
Intervention: fractional laser plus topical lidocaine cream (Group LaserAnes)
Number of subjects: 22
Study 27419471 — intervention group
Group type: COMPARATOR
Intervention: sham irradiation plus topical anesthesia (Group Anes)
Number of subjects: 22
Study 27419471 — intervention group
Group type: COMPARATOR
Intervention: sham irradiation plus sham anesthesia (Group Con)
Number of subjects: 22
Study 27419471 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LaserAnes
Number of subjects: 22
Study 27419471 — intervention group
Group type: COMPARATOR
Intervention: Group Anes
Number of subjects: 22
Study 23900888 — intervention group
Group type: EXPERIMENTAL
Intervention: Silk sericin-releasing wound dressing
Number of subjects: 0
Study 23900888 — intervention group
Group type: COMPARATOR
Intervention: Bactigras®
Number of subjects: 0
Study 22239857 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor Adventure Group (OAG)
Number of subjects: 33
Study 22239857 — intervention group
Group type: COMPARATOR
Intervention: Other Psychosocial Recovery Group Program groups (Control)
Number of subjects: 33
Study 19686437 — intervention group
Group type: EXPERIMENTAL
Intervention: HGM-3 index
Number of subjects: 195
Study 18006189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15 mg/kg orally dissolving tablet)
Number of subjects: 106
Study 18006189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 18006189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 106
Study 16356219 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative goal-directed therapy (GDT)
Number of subjects: 122
Study 16356219 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (control)
Number of subjects: 122
Study 12434938 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical nutrition therapy (MNT)
Number of subjects: 90
Study 12434938 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 90
Study 10526909 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham criteria
Number of subjects: 946
Study 10526909 — intervention group
Group type: EXPERIMENTAL
Intervention: De Simone et al. criteria
Number of subjects: 946
Study 10526909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell‐Penn criteria
Number of subjects: 946
Study 10526909 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham or De Simone et al. criteria
Number of subjects: 946
Study 10526909 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric hypertrophy
Number of subjects: 946
Study 10526909 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric remodelling
Number of subjects: 946
Study 10526909 — intervention group
Group type: EXPERIMENTAL
Intervention: No evidence of left ventricular structural alterations
Number of subjects: 946
Study 10526909 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, gender, systolic blood pressure, pulse pressure, body mass index
Number of subjects: 946
Study 7723649 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated climbing
Number of subjects: 11
Study 7723649 — intervention group
Group type: COMPARATOR
Intervention: Treadmill running
Number of subjects: 11
Study 7723649 — intervention group
Group type: COMPARATOR
Intervention: Rowing ergometry
Number of subjects: 11
Study 1675329 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy home service (6-week comprehensive programme)
Number of subjects: 105
Study 1675329 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment for 6 weeks)
Number of subjects: 105
Study 7026020 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFP (cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone)
Number of subjects: 51
Study 7026020 — intervention group
Group type: COMPARATOR
Intervention: VAC (vincristine, Adriamycin, and cyclophosphamide)
Number of subjects: 51
Study 7026020 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFP
Number of subjects: 51
Study 7026020 — intervention group
Group type: COMPARATOR
Intervention: VAC
Number of subjects: 51
Study 30943735 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC)
Number of subjects: 281
Study 30943735 — intervention group
Group type: COMPARATOR
Intervention: Standard oncologic care (SOC)
Number of subjects: 281
Study 29411520 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer containing 4-t-butylcyclohexanol and licochalcone A
Number of subjects: 80
Study 29411520 — intervention group
Group type: COMPARATOR
Intervention: 0.02% triamcinolone acetonide cream
Number of subjects: 80
Study 26932305 — intervention group
Group type: COMPARATOR
Intervention: Vildagliptin/metformin FDC tablets (50/250 mg)
Number of subjects: 0
Study 26932305 — intervention group
Group type: COMPARATOR
Intervention: Vildagliptin/metformin FDC tablets (50/500 mg)
Number of subjects: 0
Study 26932305 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin/metformin FDC tablets (50/500 mg) after meals
Number of subjects: 0
Study 26932305 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin under fed condition
Number of subjects: 0
Study 22616928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceram X mono
Number of subjects: 80
Study 22616928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceram X mono + Ribbond
Number of subjects: 80
Study 22616928 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek P90
Number of subjects: 80
Study 22616928 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek P90 + Ribbond
Number of subjects: 80
Study 21034895 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-capacity forceps
Number of subjects: 65
Study 21034895 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard forceps
Number of subjects: 65
Study 21034895 — intervention group
Group type: COMPARATOR
Intervention: Jumbo forceps
Number of subjects: 65
Study 17488783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 0
Study 17488783 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic interpersonal therapy
Number of subjects: 0
Study 17488783 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 0
Study 17488783 — intervention group
Group type: EXPERIMENTAL
Intervention: Antispasmodics
Number of subjects: 0
Study 17488783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0
Study 17488783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispaghula
Number of subjects: 0
Study 17488783 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonists
Number of subjects: 0
Study 17488783 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT4 agonists
Number of subjects: 0
Study 17488783 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 0
Study 16084157 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide + tenecteplase (0.25 mg/kg intravenous bolus)
Number of subjects: 148
Study 16084157 — intervention group
Group type: COMPARATOR
Intervention: eptifibatide + placebo
Number of subjects: 148
Study 12373040 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) consisting of transdermal application of continuous 17beta‐estradiol with cyclic medroxyprogesterone acetate (MPA) tablets for 14 days every 3rd month
Number of subjects: 0
Study 12373040 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10197835 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (2.5 mg 3 times daily) for 10 days
Number of subjects: 80
Study 10197835 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times daily) for 10 days
Number of subjects: 80
Study 7572723 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt containing active cultures
Number of subjects: 14
Study 7572723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized yogurt
Number of subjects: 14
Study 7572723 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 14
Study 2179850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin E (dl-alpha-tocopherol) on days 1, 2, 4, and 6 of life
Number of subjects: 149
Study 2179850 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo injections on the same schedule
Number of subjects: 149
Study 2179850 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E treatment in survivors
Number of subjects: 149
Study 7247587 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate sodium diet with chlorthalidone
Number of subjects: 12
Study 7247587 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate sodium diet with hydrochlorothiazide
Number of subjects: 12
Study 7247587 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate sodium diet with furosemide
Number of subjects: 12
Study 7247587 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sodium diet with chlorthalidone
Number of subjects: 12
Study 7247587 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sodium diet with hydrochlorothiazide
Number of subjects: 12
Study 7247587 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sodium diet with furosemide
Number of subjects: 12
Study 31455085 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education
Number of subjects: 300
Study 31455085 — intervention group
Group type: COMPARATOR
Intervention: Individual education
Number of subjects: 300
Study 30281813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth brushing once daily
Number of subjects: 345
Study 30281813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth brushing twice daily
Number of subjects: 345
Study 30281813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth brushing three times daily
Number of subjects: 345
Study 27894329 — intervention group
Group type: EXPERIMENTAL
Intervention: Early controlled motion of the ankle in weeks 3-8 after rupture
Number of subjects: 130
Study 27894329 — intervention group
Group type: COMPARATOR
Intervention: Control group (immobilization)
Number of subjects: 130
Study 24219618 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose paracetamol (40 mg/kg body weight, max 2000 mg)
Number of subjects: 51
Study 24219618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 24219618 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose paracetamol
Number of subjects: 51
Study 22948036 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (13‐15 mg/kg/day for 4 weeks)
Number of subjects: 112
Study 22948036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112